Hideyasu Matsuyama
Overview
Explore the profile of Hideyasu Matsuyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
212
Citations
1749
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suzuki K, Matsuyama H, Matsubara N, Kazama H, Ueno F, Uemura H
Int J Urol
. 2025 Feb;
PMID: 39996439
The incidence of prostate cancer (PC) has recently increased in Japan. Androgen deprivation therapy (ADT) has been a key treatment in patients with castration-sensitive PC (CSPC); however, resistance typically emerges...
2.
Blas L, Shiota M, Matsuyama H, Kamoto T, Enokida H, Fujimoto N, et al.
World J Urol
. 2024 Oct;
42(1):604.
PMID: 39472345
Purpose: No study has compared cancer regression (d) and growth (g) rates in patients with advanced castration-sensitive prostate cancer (CSPC) treated with androgen deprivation therapy. The comparison of d and...
3.
Kohjimoto Y, Uemura H, Yoshida M, Hinotsu S, Takahashi S, Takeuchi T, et al.
Int J Urol
. 2024 Jul;
31(11):1180-1222.
PMID: 39078210
This fourth edition of the Japanese Clinical Practice Guidelines for Prostate Cancer 2023 is compiled. It was revised under the leadership of the Japanese Urological Association, with members selected from...
4.
Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, et al.
J Immunol
. 2024 May;
213(1):23-28.
PMID: 38758119
Immune checkpoint blockade therapies are widely used for cancer treatment, including advanced renal cell carcinoma (RCC). This study aimed to investigate the impact of zygosity in HLA genes and individual...
5.
Kawai T, Matsuyama H, Kobayashi K, Ikeda A, Miyake M, Nishimoto K, et al.
Int J Urol
. 2024 May;
31(8):906-912.
PMID: 38695571
Objectives: In a primary analysis of data from the BRIGHT study (UMIN000035712), photodynamic diagnosis-assisted transurethral resection of bladder tumor (PDD-TURBT) using oral 5-aminolevulinic acid hydrochloride reduced residual tumors in high-risk...
6.
Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, et al.
Int J Urol
. 2024 Apr;
31(8):876-885.
PMID: 38687165
Objectives: The aim of this study was to compare clinical outcomes between patients receiving second TUR after initial white-light transurethral resection of bladder tumor (WL-TURBT) and initial photodynamic diagnosis (PDD)-assisted...
7.
Zhang X, Nakajima K, Mizokami A, Horikoshi H, Nishimoto K, Hashine K, et al.
Ann Nucl Med
. 2024 Mar;
38(6):428-440.
PMID: 38478154
Objective: This study aimed to determine the prognostic value of the flare phenomenon in patients with metastatic castration-resistant prostate cancer (mCRPC) using the bone scan index (BSI) derived from Tc-methylenediphosphonate...
8.
Miyake M, Kitamura H, Nishimura N, Miyamoto T, Nakahama T, Fujii T, et al.
BJUI Compass
. 2024 Feb;
5(2):269-280.
PMID: 38371197
Objective: The objective of this study is to validate the predictive ability of the 2021 European Association of Urology (EAU) risk model compared to that of existing risk models, including...
9.
Shiota M, Tanegashima T, Tatarano S, Kamoto T, Matsuyama H, Sakai H, et al.
Prostate Cancer Prostatic Dis
. 2024 Feb;
28(1):193-201.
PMID: 38368501
Background: Immune editing, in which human leukocyte antigens (HLA) have critical roles, has been suggested to shape the landscape of human cancer. This study prospectively investigated whether HLA gene zygosity...
10.
Miyake H, Matsumoto R, Fujimoto K, Mizokami A, Uemura H, Kamoto T, et al.
Eur Urol Oncol
. 2024 Jan;
7(3):625-632.
PMID: 38296736
Background: Androgen deprivation therapy (ADT), administered alone, as combined androgen blockade (CAB) or as ADT plus androgen receptor signalling inhibitors (ARSIs) or ADT plus docetaxel, is the standard treatment for...